Binimetinib + Nivolumab
Phase 2TerminatedDevelopment Stage
Clinical Stage III Cutaneous Melanoma AJCC V8
Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Unresectable Cutaneous Melanoma
Dec 3, 2020 → Nov 22, 2024
About Binimetinib + Nivolumab
Binimetinib + Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Clinical Stage III Cutaneous Melanoma AJCC V8. The current trial status is terminated. This product is registered under clinical trial identifier NCT04375527. Target conditions include Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Locally Advanced Cutaneous Melanoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04375527 | Phase 2 | Terminated |
Competing Products
20 competing products in Clinical Stage III Cutaneous Melanoma AJCC V8